喀麦隆妇女沙眼衣原体血清学诊断及生殖器致癌人瘤病 毒分子检测
摘要
眼衣原体被认为是辅助因素。我们的目标是表征高风险（小时）HPV 类型，并在患有和不患有宫颈癌的喀麦隆妇女中检
测沙眼衣原体抗体。方法：这项无与伦比的病例对照研究在杜阿拉和雅温得（喀麦隆）的四家参考医院招募了 100 例宫颈
癌患者和 200 例年龄在 25-65 岁之间细胞学正常的对照组。同意的参与者填写了一份结构化问卷和收集的社会人口特征数
据。采用酶联免疫吸附测定技术（ELISA）检测沙眼衣原体抗体，PCR 技术检测 HR HPV-DNA。进行描述性统计以提供
频率和百分比，并进行逻辑回归分析以评估分类数据之间的关联。p < 0.05 被认为是显著的。结果：我们的数据显示 39 例
（39.0%）病例年龄在 39-52 岁之间，而 96 例（48.0%）对照年龄在 25-38 岁之间（p=0.001）。我们发现 82 例（82.0%）
病例，而 HR HPV 感染对照组为 131 例（65.5%）。HPV 16 在 29 例（29.0%）病例中最为普遍，而对照组为 69 例（34.5%）。
沙眼衣原体 IgG / hr HPV 合并感染在 20 例（20.0%）病例中检测到，而对照组为 33 例（16.5%），但与宫颈癌无显着关联
（aOR=1.87;95%CI：0.58-5.97;p=0.293）。沙眼衣原体 IgM（aOR=3.50;95%CI：1.16-10.49;p=0.025）与宫颈癌显著相关。结论：
Hr HPV-DNA 在病例中高于对照组。沙眼衣原体单一感染和沙眼衣原体 / 小时 HPV 合并感染与癌前病变没有显着相关性，
因此需要进一步研究。
关键词
全文:
PDF镜像
|参考
[1] Manga MM, Fowotade A, Abdullahi YM, El-nafaty
AU, Adamu DB, Pindiga HU, Bakare RA and Osoba AO.
Epidemiological patterns of cervical human papillomavirus
infection among women presenting for cervical cancer
screening in North-Eastern Nigeria. Infect Agents Cancer. 2
October 2015; 10: 39.
[2] Owki LA, Othieno E, Wandabwa J, Okoth A.
Prevalence of cancerous and pre-malignant lesions of cervical
cancer and their association with risk factors as seen among
women in the regions of Uganda. J Clinic Laboratory Med. 8
Marsh 2017; 2.1.
[3] Bouassa R-S M, Prazuck T; Lethu T, Jenabian M-A,
Meye J-F; Bélec L. Cervical cancer in sub-Saharan Africa: a
preventable noncommunicable disease. Expert Review of Anti_xfffe_infective Therapy. 5 May 2017; 15 (6): 613-627.
[4] Ghittoni R, Accardi R, Chiocca S and Tommasino M.
Role of human papilloma viruses in carcinogenesis. ecancer. 29
April 2015; 9: 526.
[5] Clarke MA, Rodriguez AC, Gage JC, Herrero R,
Hildesheim A, Wacholder S, Schiffman RBM. A large,
population-based study of age-related associations between
vaginal pH and human papillomavirus infection. BMC Infect
Dis. 8 February 2012, 12: 33.
[6] Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK &
Sreenivas V. Association of Chlamydia trachomatis infection
with human papillomavirus (HPV) & cervical intraepithelial
neoplasia - A pilot study. Indian J Med Res. Marsh 2013; 137:
533-539.
[7] Parthenisa C, Panagopoulosa P, Margarib N, Kottaridib
C, Spathis A, Pouliakis A, Konstantoudakis S, Chreliasa G,
Chreliasa C, Papantonioua N, Ioannis G. Panayiotides,Tsiodras
S. The association between sexually transmitted infections,
human papilloma virus, and cervical cytology abnormalities
among women in Greece. Intern J Infect Dis. 5 June 2018; 73:
72–77.
[8] Malhotra M, Sood S, Mukherjee A, Muralidhar S &
Bala M. Genital Chlamydia trachomatis: An update. Indian J
Med Res. October 2013; 138: 33-316.
[9] Richard PM. New insights into a persistent problem:
Chlamydia infections. J. Clin. Invest. 1 June 2003; 111: 1647–
1649.
[10] Bekolo CE, O’Bryan G, Tchago FE, Nangue C,
Bekoule PS, Kollo B. Integrating cervical cancer screening with
HIV care in Cameroon: Comparative Risk Analysis of Cervical
Disease in HIV-infected women receiving antiretroviral therapy
to women in the general Population. PLoS ONE. 11 February
2016, 11 (2): e0149152.
[11] De Castro-Sobrinho JM, Rabelo-Santos SH, Alves
RRF, Derchain S, Sarian LOZ, Pitta DR, Campos EA and
Zeferino LC. Chlamydia trachomatis Co-infection in HPV
Positive Women brings no Additional Risk of High-grade
Cervical Intraepithelial Neoplasia. J Cytol Histol. November
20, 2015, S3: 2.
[12] Zhu H, Shen Z, Luo H, Zhang W, and Zhu X.
Chlamydia Trachomatis Infection- Associated Risk of Cervical
Cancer. A Meta-Analysis. Medicine. Marsh 2016: 95 (13):
e377).
[13] Samoff E, Koumans EH, Markowitz LE, Sternberg
M, Sawyer MK, Swan D, Papp JR, Black CM, and Unger ER.
Association of Chlamydia trachomatis with Persistence of High_xfffe_Risk Types of Human Papillomavirus in a Cohort of Female
Adolescents. Am J Epidemiol. January 13, 2005; 162: pp 668-
675.
[14] Tungsrithong N, Kasinpila C, Maneenin C, Namujju
PB, Lehtinen M, Anttila A, Promthet S. Lack of Significant
Effects of Chlamydia trachomatis Infection on Cervical Cancer
Risk in a Nested Case-Control Study in North-East Thailand.
Asian Pacific J Cancer Prev. 15 July 2014; 15 (3): 1497-1500.
[15] Charan J and Biswas T. How to Calculate Sample
Size for Different Study Designs in Medical Research? Indian J
Psychol Med. April- June 2013; 35 (2): 121–126.
[16] Doh G, Ikomey MG, Njenda D, Gichana J, Katusiime
MG, Ndze VN, Zeier M, Mesembe M, Fokunang C, Assoumou
OCM, Tebeu PM, Atangana PA, Jacobs GB. Oncogenic Human
Papillomavirus Genotypes 16 and 18 Prevalence Among
Women with Normal Cervical Cytology and Neoplasia in
Cameroon: A Systematic Review. Health Sci. Dis: August_xfffe_September 2017; 18 (3).
[17] Debrah O, Agyemang-Yeboah F, Asmah RH, Timmy_xfffe_Donkoh E, Seini MM, Fondjo LA, Nilok Sight and Owusu_xfffe_Dabo E. Sero-prevalence of herpes simplex virus type 1 and
type 2 among women attending routine Cervicare clinics in
Ghana. BMC Infect Dis. 7 August 2018; 18: 378.
[18] Sankaranarayanan R, Wesley RS. A Practical Manual
on Visual Screening for Cervical Neoplasia IARC Technical
Publication No. 41 IARC Press, 2003.
[19] Sharmaa P, Pattanshetty SM. A study on risk factors
of cervical cancer among patients attending a tertiary care
hospital: A case-control study. Clinic Epidemiol Global Health
6 3 October 2017; 2018; 83-87.
[20] Mohann P, Shetty S. A Case Control Study on the
Risk Factors of Cervical Cancer among Women in a Coastal
City of South India. Intern J Sci Research (IJSR). July 2015; 4
(7): 2049-2051.
[21] Kalgong G, Kamdje NHA, Tagne SR, Nangue C.
Sensitivity and specificity of visual inspection with acetic acid
(VIA) and with Lugol Iodine (VILI) in the diagnosis of cervical
cancer in the Northern Region of Cameroon. Int. Biol. Biomed.
J. 25 Marsh 2017; 3 (2).
[22] Girgis SA, kassem NN and Eltohamy OA. Chlamydia
trachomatis and Human Papilloma Virus (HPV) infection in
Egyptian Patients with Invasive Cancer Cervix- A Case Control
Study. Int. J. Curr. Microbiol. App. Sci. Volume 4 Number 6
(2015) pp. 937-949.
[23] Damião PDA, Oliveira-Silva M, Moreira MA,
Poliakova N, De Lima MERT, Chiovo J, Nicol AF,& Human
Papillomavirus types distribution among women with cervical
preneoplastic, lesions and cancer in Luanda, Angola. Pan Afr
Med J. 22 July 2016; 24: 268.
[24] Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK,
O’Reilly SF, Kiviat NB, and Koutsky LA. Prevalence and risk
factors for oncogenic HPV infections in high-risk mid-adult
women. Sex Transm Dis. November 2012; 39 (11): 848-856.
[25] Wohlmeister D, Vianna DRB, Helfer VE, Gimenes
F, Consolaro MEL, Barcellos RB, Rossetti ML, Calil LN,
Buffon A, Pilger DA. Association of human papillomavirus and
Chlamydia trachomatis with intraepithelial alterations in cervix
samples. Mem Inst Oswaldo Cruz, Rio de Janeiro. February
2016; 111 (2): 106-113.
[26] Natphopsuk S, Settheetham-Ishida W, Sinawat S,
Pientong C, Yuenyao P, Shida T. Risk factors for cervical in
Northern eastern Thaland: detailed analyses of sexual and
smoking behaviour. Asian Pacific J cancer. November 2012; 13
(11): 5489-5495.
[27] Okechukwu A. Ibeanu. Molecular pathogenesis of
cervical cancer. Cancer Biol Therapy. 1 February 2011. 11 (3):
295-306.
[28] Pirek D, Petignat P, Vassilakos P, Gourmaud J,
Pache JC, Rubbia-Brandt L, Zacharie Sando Z, McKee,
Liza Ho TA. Human papillomavirus genotype distribution
among Cameroonian women with invasive cervical cancer: a
retrospective study. Sex Transm Infect. 6 Marsh 2015; 91: 440-
444.
[29] Omar VE, Orvalho A, Nália I, Malin K, Gabriella
LL, Torbjörn R, Charlotta N, Kerstin F, Nafissa O, Vindorai
JI, Sören A. Human papillomavirus prevalence and genotype
distribution among young women and men in Maputo city,
Mozambique. BMJ Open 17 July 2017; 7: e015653.
[30] Okunade KS, Nwogu CM, Oluwole AA. Anorlu
RI. Prevalence and risk factors for genital high-risk human
papillomavirus infection among women attending the outpatient
clinics of a university teaching hospital in Lagos, Nigeria. Pan
Afr Med J. 14 November 2017; 28: 227.
[31] Muvunyi CM, Dhont N, Verhelst R, Temmerman
M, Claeys G, and Padalko E. Chlamydia trachomatis infection
in fertile and subfertile women in Rwanda: prevalence and
diagnostic significance of IgG and IgA antibodies testing.
Human Reprod. 20 October 2011; 26, (12): 3319-3326.
[32] Rowley J, Hoorn SV, Korenromp E, Low N, Unemo
M, AbuRaddad LJ, Chico RM, Smolak A, Newman L,
Gottlieb S, Thwin SS, Brouteta N & Taylora MM. Chlamydia,
gonorrhoea, trichomoniasis and syphilis: global prevalence and
incidence estimates, 2016. Bull World Health Organ. 1 August
2019; 97: 548–562.
[33] Ige OT, Ige SO, Olayinka AT. Prevalence of
Chlamydia Trachomatis infection among women of reproductive
age group in a tertiary hospital in Northern Nigeria. Ann Trop
Pathol. 24 October 2018; 9: 17-21.
[34] Deluca GD, Schelover JBE, Vásquez ND, Alonso JM,
Marín HM, Lucero RH, Picconi MA. Chlamydia trachomatis
as a probable cofactor in human papillomavirus infection in
aboriginal women from northeastern Argentina. Braz J Infect
Dis. November-December 2011; 15 (6): 567-572.
[35] Pinto VM, Tancredi MV, De Carvalho da Silva RJ,
Khoury Z and Buchalla CM. Prevalence and factors associated
with Chlamydia trachomatis infection among women with HIV
in São Paulo. Rev Soc Bras Med Trop. May-June 2016; 49 (3):
312-318.
[36] Adegbesan-Omilabu MA, Okunade KS, Oluwole AA,
Gbadegesin A, Omilabu SA. Chlamydia trachomatis among
women with normal and abnormal cervical smears in Lagos,
Nigeria. Int J Reprod Contracept Obstet Gynecol. 21 August
2014; 3 (3): 501-506.
[37] Kwaśniewska A, Skoczyński M, Korobowicz
E, Semczuk M, and Goździcka-Józefiak A. Prevalence of
chlamydia trachomatis in cervical and vulvar carcinoma of the
Lublin region patients. Bull Vet Inst Pulawy. 18 July 2007; 51:
357-360.
[38] Naucler P, Chen H-C, Persson K, You S-L, Hsieh
C-Y, Sun C-A, Dillner J and Chen C-J. Seroprevalence of
human papillomaviruses and Chlamydia trachomatis and
cervical cancer risk: nested case–control study. J Gen Virol. 24
November 2007; 88: 814-822.
[39] Ssedyabane F, Amnia DA, Mayanja R, Omonigho
A, Ssuuna C, Najjuma JN, and Freddie B. HPV-Chlamydial
Co-infection, Prevalence, and Association with Cervical
Intraepithelial Lesions: A Pilot Study at Mbarara Regional
Referral Hospital. J Cancer Epidemiol. 10 January 2019: (7).
[40] Javanmard D, Behravan M, Ghannadkafi M,
Salehabadi A, Ziaee M, Namaei MH. Detection of Chlamydia
trachomatis in Pap Smear Samples from South Khorasan
Province of Iran. Int J Fertil Steril. 15 January 2018; 12 (1): 31-
36.
[41] Silins I, Ryd W, Strand A, Wadell G, To¨rnberg S,
Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson
K, Dillner J and Rylander E. Chlamydia trachomatis infection
and persistence of human papillomavirus. Int. J. Cancer. 8
March 2005; 116: 110-115.
[42] Smelov V, Gheit T, Sundström K, Ploner A, McKayChopin S, Eklund C, Tommasino M, Dillner J. Lack of
Significant Effects of Chlamydia trachomatis Infection on
Cervical Adenocarcinoma Risk: Nested Case-Control Study.
PLoS ONE. May 26, 2016; 11 (5): e0156215.
Refbacks
- 当前没有refback。
数据库合作单位
